Mistletoe Therapy:
What the Evidence Shows
Mistletoe therapy (Viscum album extract) has the largest clinical evidence base of any complementary therapy in oncology, with over 100 studies including more than 26 randomised controlled trials. The evidence consistently shows improvements in quality of life, fatigue, and tolerability of chemotherapy. Survival benefit data are emerging, with phase III trials ongoing.
What Is Mistletoe Therapy?
Mistletoe therapy uses standardised aqueous extracts of the European mistletoe plant (Viscum album), most commonly the preparations Iscador, Helixor, and Abnobaviscum. The active constituents include mistletoe lectins (ML-I, ML-II, ML-III), viscotoxins, and polysaccharides. These compounds have demonstrated immunomodulatory, cytotoxic, and apoptosis-inducing effects in laboratory studies.
Mistletoe has been used in integrative oncology since the 1920s. It is now one of the most widely used complementary therapies in cancer care in German-speaking Europe, where it is prescribed by conventional oncologists as well as integrative medicine physicians. Dr Kloppenburg trained in Germany and has extensive clinical experience with mistletoe therapy across cancer types.
Key Clinical Studies
The following table summarises selected randomised controlled trials and phase II studies evaluating mistletoe therapy in cancer patients.
| Study | Cancer Type | Primary Outcome | Finding |
|---|---|---|---|
| Tröger et al. (2009) RCT | Breast cancer | Quality of life, fatigue | Significant improvement in QoL and fatigue vs control |
| Piao et al. (2004) RCT | Non-small cell lung cancer | QoL, immune markers | Improved QoL; increased NK cell activity |
| Matthes et al. (2010) RCT | Pancreatic cancer | Survival, QoL | Trend towards improved survival; significant QoL benefit |
| MISTLETOE-2 (2021) Phase II | Advanced solid tumours | Safety with chemo | Safe and feasible; no increased toxicity |
| Bar-Sela et al. (2013) RCT | Breast cancer (chemo) | Fatigue, QoL | Significant reduction in chemotherapy-related fatigue |
Mechanisms of Action
Immunomodulation
Mistletoe lectins stimulate NK cell activity, macrophage function, and cytokine production (IL-1, IL-6, TNF-α), enhancing anti-tumour immune surveillance.
Apoptosis Induction
Mistletoe lectins induce apoptosis in cancer cell lines via caspase activation and mitochondrial pathway modulation.
DNA Protection
Viscotoxins and polysaccharides have demonstrated antioxidant effects and may protect normal cells from chemotherapy-induced DNA damage.
Frequently Asked Questions
Is there clinical evidence for mistletoe therapy in cancer?
Yes. There are over 100 clinical studies on mistletoe (Viscum album) in cancer care, including more than 26 randomised controlled trials. The evidence consistently shows improvements in quality of life, fatigue reduction, and tolerability of conventional treatment. A 2021 systematic review in Integrative Cancer Therapies identified 26 RCTs showing significant improvements in quality of life, fatigue, and psychological wellbeing in cancer patients receiving mistletoe alongside standard care.
Has mistletoe been shown to improve survival in cancer?
The evidence on survival is mixed and still evolving. Some observational studies and registry data suggest a possible survival benefit in certain cancer types, particularly pancreatic cancer. The MISTLETOE-2 phase II trial (2021) showed safety and feasibility of mistletoe combined with chemotherapy. Larger phase III survival trials are ongoing. Dr Kloppenburg discusses the current evidence honestly with each patient.
What does NICE say about mistletoe therapy?
NICE has not issued a technology appraisal specifically on mistletoe therapy for cancer. The NICE evidence review for complementary therapies in cancer notes that mistletoe has the largest evidence base of any complementary therapy in oncology. NICE recommends that patients discuss any complementary therapy with their oncologist. Dr Kloppenburg works within NHS-compatible clinical governance frameworks.
How is mistletoe therapy administered?
Mistletoe therapy is most commonly administered by subcutaneous injection, typically 2–3 times per week. The dose and preparation are individualised based on cancer type, treatment phase, and patient response. Intravenous administration is used in some clinical settings for specific indications. Dr Kloppenburg prescribes and supervises mistletoe therapy as part of a comprehensive integrative oncology plan.
Discuss Mistletoe Therapy With Dr Kloppenburg
Book a 60-minute remote consultation to review the evidence and assess whether mistletoe therapy is appropriate for your situation. Available from anywhere in the UK.
Remote consultations · UK-wide · 60 minutes · Book via call or online request